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1 Introduction
 A staggering one third of all humans are affected 
by insomnia. Sleep-related complaints are also dispro-
portionately high in prevalence in medical practice. This 
malady, which was once thought to be an innocuous 
annoyance, is now known to impair normal human func-
tion, to cause a variety of medical and psychiatric disor-
ders, and even to limit lifespan. For medical practitioners, 
therefore, the proper identi¿ cation, clinical evaluation, 
and effective management of insomnia are of signi¿ cant 
importance. 
 In this book, we take a systematic approach in 
inform ing the primary care practitioner in the evaluation 
and management of insomnia. In Chapter 2, we begin 
with a foundation in normal sleep neurophysiology. The 
past few decades have seen a tremendous advance in our 
understanding of the central underpinnings of sleep and 
wakefulness. We now know that this seemingly quiescent 
state is the product of a complex array of interactions that 
produce a balance between wake-promoting systems on 
the one hand, governed by norepinephrine, serotonin, 
dopamine, acetylcholine, and histamine, and sleep-pro-
moting systems on the other hand, governed by GABA 
and galanin and under the circadian influence of the 
hormone melatonin. Newly discovered neurotransmitters, 
the orexins/hypocretins, play a critical role in maintaining 
an orderly transition between these two states. 
 In Chapters 3 through 6, we present the most 
recent diagnostic guidelines for insomnia. We explore 
key developments in clarifying the pathophysiology of 
insomnia, and explain how these have led to an evolution 
of our view of the relationship between co-occurring 
insomnia and medical/psychiatric disorders from a model 
of unidirectional causality to one of autonomous disor-
ders interacting in a bidirectional fashion. We also delve 
into an in-depth review of the many consequences of this 
disorder. 
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 In Chapters 7 and 8, we present some of the most 
important aspects of insomnia for clinical practitioners, 
ie, its evaluation and management. We stress the impor-
tance of a thorough of¿ ce-based evaluation, and present 
guidelines for this endeavor based on the most recent 
practice parameter statements. We emphasize the impor-
tance of treatment that is focused on underlying cause, 
as opposed to the uninformed entry into symptomatic 
management. In Chapters 9 through 11, we explore the 
many available pharmacologic agents for the treatment 
of insomnia and provide an evidence-based approach 
in their selection and use. Whereas GABA receptor 
agonists have traditionally dominated the therapeutic 
armamentarium, we review novel and investigational 
agents with mechanisms traversing the receptor systems 
that are involved in the control of sleep and arousal, such 
as selective histamine H1 receptor antagonists, selective 
melatonin receptor agonists, and dual orexin receptor 
antagonists. “Natural” compounds enjoy a signi¿ cant 
allure by virtue of their widespread availability and the 
perception that they are safer than prescription medica-
tions for insomnia. We explore the vast array of such 
products utilized for sleep-related complaints and provide 
empirical data to guide practitioners through the morass 
of claims regarding the bene¿ ts of these agents. Although 
less widely utilized than pharmacologic agents, cognitive 
and behavioral therapies are of clear bene¿ t in insomnia. 
We explore the principles underlying these techniques 
and guidelines in their implementation. We also review 
exciting new evidence demonstrating the lasting bene¿ t 
of these therapies for extended periods of time following 
termination of treatment.
 Throughout the book, we are guided by our main 
goal of providing practitioners with clinically relevant, 
evidence-based, and state-of-the-art information in the 
evaluation and management of insomnia. We have made 
a concerted attempt to ensure that our reviews are consis-
tent with professional guidelines to the extent that current 
knowledge permits. Nevertheless, we remind our readers 
that scienti¿ c discovery is ongoing. Since the publica-
tion of this textbook, certain guidelines and standards 
for treatment may already have changed. In addition, in 
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clinical practice, medications may be used for indications 
and at doses that are not covered by the package label. 
Therefore we advise readers to consult the peer-reviewed 
literature, as well as product labels, to obtain the most 
up-to-date information regarding recommended doses, 
safety pro¿ les, indications, and other guidelines. Useful 
resources include the FDA website (http://www.access-
data.fda.gov/scripts/cder/drugsatfda/index.cfm) and FDA 
safety alerts at http://www.fda.gov/Safety/Recalls/default.
htm. 
